prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55 |56 |57 |58 |59 |60 |review

Key Point: The occurrence of clinically relevant CK elevations with greater LDL-C reductions is low in patients receiving rosuvastatin 10 mg to 40 mg, indicating a favorable benefit-risk profile.

This slide shows a benefit-risk assessment for statin therapies. The occurrence of CK elevations >10 ULN are plotted against percent LDL-C reductions for various statins by dose

As shown, this graph suggests most of the statins exhibit an increasing occurrence of clinically relevant CK elevations with increasing LDL-C reductions as the dose is increased

However, the occurrence of clinically relevant CK elevations with greater LDL-C reductions remains low in patients receiving rosuvastatin 10 mg to 40 mg, indicating a favorable benefit-risk profile
 

Please note that the data for this analysis were derived from prescribing information,
summary basis of approvals, clinical trials, and other sources. Prospectively designed comparative clinical trials were not utilized in this analysis and results should be interpreted with caution.